Jump to Main Content
- Velculescu, Victor E., et al. Show all 18 Authors
- Cell 2017 v.171 no.6 pp. 1284-1300.e21
- DNA; T-lymphocytes; animal models; antigen presentation; antineoplastic activity; cell lines; chemoattractants; chemokine CCL5; clinical trials; double-stranded RNA; enzyme inhibitors; epigenetics; gene expression regulation; histone deacetylase; immune evasion; interferons; lung neoplasms; memory; methyltransferases; phenotype; therapeutics; transcription (genetics)
- ... Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune therapy. Herein, pharmacologic and isoform specificity of HDACis are investigated to guide their addition to a DNMTi, thus devising a new, low-dose, sequential regimen that imparts a robust anti-tumor effect for non-small-cell lung ca ...
- PubMed Central: